ClinicalTrials.gg
CompletedNCT02447302Updated Apr 5, 2021Results posted

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

A Phase 2 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 134 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-05.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
7th of 12
156 · median 195
Started
2015
the only one that year
Phase 2
6 of 12
2 open now
Registered
1st of 12
by date
Lead sponsor
4 of 12
Arena Pharmaceuticals

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 2, and was the 1st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic score
  • Evidence of colonic ulcerative colitis activity on endoscopy

Exclusion criteria

Exclusion Criteria:

  • Within 30 days prior to randomization, receipt of any of the following for the treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus, tofacitinib, thalidomide), a non-biologic therapy or an approved non-biologic therapy in an investigational protocol
  • Within 60 days prior to randomization, receipt of any of the following: Infliximab, adalimumab, golimumab, certolizumab, vedolizumab, any other investigational or approved biologic agent
  • Any prior exposure to natalizumab, efalizumab, or rituximab
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Etrasimod Low Dose

    Oral, low dose, daily for 12 Weeks

    Drug: Etrasimod

  • Experimental
    Etrasimod High Dose

    Oral, high dose, daily for 12 weeks

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Oral, placebo, daily for 12 weeks.

    Drug: Placebo

Interventions

  • Also known as: APD334

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Adapted Mayo Score (MCS) at Week 12

    The adapted MCS was used to measure disease activity of ulcerative colitis. It consisted of 3 subscores (stool frequency, rectal bleeding, and findings of endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The adapted MCS was calculated as the sum of the 3 subscores, and the overall score values ranged from 0 to 9, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved Endoscopic Improvement at Week 12

    For determination of the endoscopic subscore of the MCS, a flexible proctosigmoidoscopy, performed with a videoendoscope following a cleansing prep (oral or rectal cathartic) was performed at screening (within 10 days prior to administration of the first dose of study drug) and the Week 12 visit. This efficacy procedure assessed endoscopic mucosal appearance. The results were rated on a scale from 0 to 3, indicating normal to severe. Endoscopic improvement was defined as Mayo endoscopic subscore (using findings of flexible proctosigmoidoscopy) of ≤1 point. Multiple imputation method was used to handle missing data.

    Time frame: Week 12

  2. Change From Baseline in 2-component MCS at Week 12

    The 2-component MCS was used to measure disease activity of ulcerative colitis. It consisted of 2 subscores (rectal bleeding and findings on endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The 2-component MCS was calculated as the sum of the 2 subscores, and the overall score value ranged from 0 to 6, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Total Mayo Score (TMS) at Week 12

    The TMS was used to measure disease activity of ulcerative colitis. It consisted of 4 subscores \[stool frequency, rectal bleeding, findings of endoscopy (flexible proctosigmoidoscopy), and Physician's Global Assessment (PGA) score\], each of which was rated on a scale from 0 to 3, indicating normal to severe. The TMS was calculated as the sum of the 4 subscores, and the overall score values ranged from 0 to 12, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.

    Time frame: Baseline and Week 12

Other outcomes

  1. Trichotomous Composite Score of Clinical Remission and Clinical Response at Week 12

    The trichotomous composite score of clinical remission and clinical response at Week 12 is an ordinal categorical endpoint with 3 categories (score ranging 0 to 2: score 2 for achieving both clinical remission and clinical response; 1 for only achieving clinical response, and 0 for achieving neither). Multiple imputation method was used to handle missing data.

    Time frame: Week 12

  2. Percentage of Participants Who Achieved Clinical Remission at Week 12

    A participant was considered to have achieved clinical remission if he/she had: 1) an endoscopy score using flexible proctosigmoidoscopy of 0 or 1 (excluding friability), 2) a rectal bleeding score of 0 or 1, and 3) a stool frequency score of 0 or 1 with a decrease of ≥1 point from baseline. Multiple imputation method was used to handle missing data.

    Time frame: Week 12

  3. Percentage of Participants Who Achieved Clinical Response at Week 12

    A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission defined above, or met criteria of clinical response. Clinical response was defined as a decrease in the adapted MCS of ≥ 2 points and a decrease of ≥ 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1.

    Time frame: Week 12

07

Results

Posted Apr 5, 2021

Participant flow

The study included a screening period (up to 28 days), a double-blind induction treatment period (12 weeks), and a possible follow-up visit (2 weeks after the last study visit). The target population consisted of male or female participants aged between 18 and 80 years (inclusive), with moderately to severely active Ulcerative Colitis.

Participant flow — Overall Study
MilestoneEtrasimod 1 mgEtrasimod 2 mgPlacebo
Started525054
Completed474648
Not completed546
Withdrew: Physician decision100
Withdrew: Adverse event430
Withdrew: Withdrawal by subject015
Withdrew: Sponsor decision001

Outcome measures

PrimaryChange From Baseline in Adapted Mayo Score (MCS) at Week 12

The adapted MCS was used to measure disease activity of ulcerative colitis. It consisted of 3 subscores (stool frequency, rectal bleeding, and findings of endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The adapted MCS was calculated as the sum of the 3 subscores, and the overall score values ranged from 0 to 9, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Adapted Mayo Score (MCS) at Week 12
score on a scaleEtrasimod 1 mgEtrasimod 2 mgPlacebo
Change From Baseline in Adapted Mayo Score (MCS) at Week 12-1.94 (-2.45 to -1.42)-2.49 (-3.01 to -1.98)-1.50 (-2.00 to -1.01)
Statistical analysis
  • Etrasimod 2 mg vs Placebo · ANCOVA · p = = 0.0091 (The analysis was performed using an analysis of covariance (ANCOVA) model that incorporated treatment, current oral corticosteroid use, prior exposure to tumor necrosis factor alpha (TNFα) antagonists, and baseline value as covariate.) · Difference in least square mean: -0.99 · 90% CI -1.68 to -0.30Estimated least square mean difference in etrasimod 2 mg from placebo
  • Etrasimod 1 mg vs Placebo · ANCOVA · p = = 0.1457 (The analysis was performed using an ANCOVA model that incorporated treatment, current oral corticosteroid use, prior exposure to TNFα antagonists, and baseline value as covariate.) · Difference in least square mean: -0.43 · 90% CI -1.11 to 0.24Estimated least square mean difference in etrasimod 1 mg from placebo
SecondaryPercentage of Participants Who Achieved Endoscopic Improvement at Week 12

For determination of the endoscopic subscore of the MCS, a flexible proctosigmoidoscopy, performed with a videoendoscope following a cleansing prep (oral or rectal cathartic) was performed at screening (within 10 days prior to administration of the first dose of study drug) and the Week 12 visit. This efficacy procedure assessed endoscopic mucosal appearance. The results were rated on a scale from 0 to 3, indicating normal to severe. Endoscopic improvement was defined as Mayo endoscopic subscore (using findings of flexible proctosigmoidoscopy) of ≤1 point. Multiple imputation method was used to handle missing data.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Endoscopic Improvement at Week 12
percentage of participantsEtrasimod 1 mgEtrasimod 2 mgPlacebo
Percentage of Participants Who Achieved Endoscopic Improvement at Week 1222.541.817.8
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Mantel Haenszel · p = = 0.003 (Mantel-Haenszel (MH) estimated common risk difference adjusted for current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists.) · Mh estimate for difference in percentage: 24.4 · 90% CI 9.8 to 39.0MH estimated difference in etrasimod 2 mg from Placebo
  • Etrasimod 1 mg vs Placebo · Mantel Haenszel · p = = 0.3059 (MH estimated common risk difference adjusted for current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists.) · Mh estimate for difference in percentage: 4.1 · 90% CI -9.1 to 17.2MH estimated difference in etrasimod 1 mg from Placebo
SecondaryChange From Baseline in 2-component MCS at Week 12

The 2-component MCS was used to measure disease activity of ulcerative colitis. It consisted of 2 subscores (rectal bleeding and findings on endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The 2-component MCS was calculated as the sum of the 2 subscores, and the overall score value ranged from 0 to 6, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in 2-component MCS at Week 12
score on a scaleEtrasimod 1 mgEtrasimod 2 mgPlacebo
Change From Baseline in 2-component MCS at Week 12-1.30 (-1.66 to -0.95)-1.75 (-2.11 to -1.40)-0.92 (-1.26 to -0.57)
Statistical analysis
  • Etrasimod 2 mg vs Placebo · ANCOVA · p = = 0.0020 (The analysis was performed using an ANCOVA model that incorporated treatment, current oral corticosteroid use, prior exposure to TNFα antagonists, and baseline value as covariate.) · Difference in least square mean: -0.84 · 90% CI -1.32 to -0.36Estimated least square mean difference in etrasimod 2 mg from placebo
  • Etrasimod 1 mg vs Placebo · ANCOVA · p = = 0.0858 (The analysis was performed using an ANCOVA model that incorporated treatment, current oral corticosteroid use, prior exposure to TNFα antagonists, and baseline value as covariate.) · Difference in least square mean: -0.39 · 90% CI -0.85 to 0.08Estimated least square mean difference in etrasimod 1 mg from placebo
SecondaryChange From Baseline in Total Mayo Score (TMS) at Week 12

The TMS was used to measure disease activity of ulcerative colitis. It consisted of 4 subscores \[stool frequency, rectal bleeding, findings of endoscopy (flexible proctosigmoidoscopy), and Physician's Global Assessment (PGA) score\], each of which was rated on a scale from 0 to 3, indicating normal to severe. The TMS was calculated as the sum of the 4 subscores, and the overall score values ranged from 0 to 12, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Total Mayo Score (TMS) at Week 12
score on a scaleEtrasimod 1 mgEtrasimod 2 mgPlacebo
Change From Baseline in Total Mayo Score (TMS) at Week 12-2.69 (-3.36 to -2.02)-3.35 (-4.03 to -2.68)-2.08 (-2.73 to -1.44)
Statistical analysis
  • Etrasimod 2 mg vs Placebo · ANCOVA · p = = 0.0100 (The analysis was performed using an ANCOVA model that incorporated treatment, current oral corticosteroid use, prior exposure to TNFα antagonists, and baseline value as covariate.) · Difference in least square mean: -1.27 · 90% CI -2.17 to -0.37Estimated least square mean difference in etrasimod 2 mg from placebo
  • Etrasimod 1 mg vs Placebo · ANCOVA · p = = 0.1277 (The analysis was performed using an ANCOVA model that incorporated treatment, current oral corticosteroid use, prior exposure to TNFα antagonists, and baseline value as covariate.) · Difference in least square mean: -0.60 · 90% CI -1.48 to 0.27Estimated least square mean difference in etrasimod 1 mg from placebo
Other pre-specifiedTrichotomous Composite Score of Clinical Remission and Clinical Response at Week 12

The trichotomous composite score of clinical remission and clinical response at Week 12 is an ordinal categorical endpoint with 3 categories (score ranging 0 to 2: score 2 for achieving both clinical remission and clinical response; 1 for only achieving clinical response, and 0 for achieving neither). Multiple imputation method was used to handle missing data.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Trichotomous Composite Score of Clinical Remission and Clinical Response at Week 12
score on a scaleEtrasimod 1 mgEtrasimod 2 mgPlacebo
Trichotomous Composite Score of Clinical Remission and Clinical Response at Week 120.60 ± 0.110.84 ± 0.130.41 ± 0.09
Statistical analysis
  • Etrasimod 2 mg vs Placebo · ANCOVA · p = = 0.0071 (The analysis was performed using an ordered logistic regression model with terms for treatment, current oral corticosteroid use, and prior exposure to TNFα antagonists.) · Odds ratio (or): 2.78 · 90% CI 1.40 to 5.51The analysis compared the odds of achieving higher trichotomous composite score between the groups using 1-sided test at 0.05 level of significance.
  • Etrasimod 1 mg vs Placebo · ANCOVA · p = = 0.1192 (The analysis was performed using an ordered logistic regression model with terms for treatment, current oral corticosteroid use, and prior exposure to TNFα antagonists.) · Odds ratio (or): 1.61 · 90% CI 0.83 to 3.14The analysis compared the odds of achieving higher trichotomous composite score between the groups using 1-sided test at 0.05 level of significance.
Other pre-specifiedPercentage of Participants Who Achieved Clinical Remission at Week 12

A participant was considered to have achieved clinical remission if he/she had: 1) an endoscopy score using flexible proctosigmoidoscopy of 0 or 1 (excluding friability), 2) a rectal bleeding score of 0 or 1, and 3) a stool frequency score of 0 or 1 with a decrease of ≥1 point from baseline. Multiple imputation method was used to handle missing data.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 12
percentage of participantsEtrasimod 1 mgEtrasimod 2 mgPlacebo
Percentage of Participants Who Achieved Clinical Remission at Week 1216.033.08.1
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Mantel Haenszel · p = = 0.0003 (The analysis was performed using MH method that was adjusted for current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists.) · Mh estimate for difference in percentage: 25.8 · 90% CI 13.5 to 38.1MH estimated difference in etrasimod 2 mg from Placebo
  • Etrasimod 1 mg vs Placebo · Mantel Haenszel · p = = 0.1360 (The analysis was performed using MH method that was adjusted for current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists.) · Mh estimate for difference in percentage: 7.1 · 90% CI -3.5 to 17.7MH estimated difference in etrasimod 1 mg from Placebo
Other pre-specifiedPercentage of Participants Who Achieved Clinical Response at Week 12

A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission defined above, or met criteria of clinical response. Clinical response was defined as a decrease in the adapted MCS of ≥ 2 points and a decrease of ≥ 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response at Week 12
percentage of participantsEtrasimod 1 mgEtrasimod 2 mgPlacebo
Percentage of Participants Who Achieved Clinical Response at Week 1243.750.632.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Mantel Haenszel · p = = 0.0282 (The analysis was performed using MH method that was adjusted for current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists.) · Mh estimate for difference in percentage: 18.9 · 90% CI 2.6 to 35.3MH estimated difference in etrasimod 2 mg from Placebo
  • Etrasimod 1 mg vs Placebo · Mantel Haenszel · p = = 0.1309 (The analysis was performed using MH method that was adjusted for current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists.) · Mh estimate for difference in percentage: 11.4 · 90% CI -5.3 to 28.1MH estimated difference in etrasimod 1 mg from Placebo

Adverse events

Collected over Up to approximately 16 weeks i.e. from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etrasimod 1 mg0/52 (0%)3/52 (5.8%)11/52 (21.2%)
Etrasimod 2 mg0/50 (0%)0/50 (0%)11/50 (22%)
Placebo0/54 (0%)6/54 (11.1%)9/54 (16.7%)
Most frequent serious events
Most frequent serious events
EventEtrasimod 1 mgEtrasimod 2 mgPlacebo
Colitis ulcerativeGastrointestinal disorders2/520/503/54
Anal abscessInfections and infestations1/520/500/54
Abdominal painGastrointestinal disorders0/520/501/54
Duodenal ulcer perforationGastrointestinal disorders0/520/501/54
JaundiceHepatobiliary disorders0/520/501/54
HydronephrosisRenal and urinary disorders0/520/501/54
Most frequent other events
Most frequent other events
EventEtrasimod 1 mgEtrasimod 2 mgPlacebo
Upper respiratory tract infectionInfections and infestations4/522/502/54
NasopharyngitisInfections and infestations2/521/504/54
HeadacheNervous system disorders0/523/501/54
AnaemiaBlood and lymphatic system disorders2/523/502/54
Colitis ulcerativeGastrointestinal disorders3/522/501/54

Baseline characteristics

The analysis was performed using the safety population that consisted of all randomized participants who received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Median44.0 (21 to 64)38.5 (21 to 67)46.0 (20 to 73)42 (20 to 73)
Age, Customized
Age, Customized(Subjects)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Adults (18-64 years)524949150
From 65-80 years0156
Sex: Female, Male
Sex: Female, Male(Participants)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Female22232267
Male30273289
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Hispanic or Latino3137
Not Hispanic or Latino494951149
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
American Indian or Alaska Native1001
Asian2125
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White474951147
More than one race1001
Unknown or Not Reported1001
Adapted Mayo Score (MCS)
Adapted Mayo Score (MCS)(score on a scale)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Mean6.5 ± 1.236.6 ± 1.176.5 ± 1.516.5 ± 1.31
The 2-component MCS
The 2-component MCS(score on a scale)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Mean4.2 ± 0.754.2 ± 0.754.2 ± 0.914.2 ± 0.80
Total Mayo Score (TMS)
Total Mayo Score (TMS)(score on a scale)Etrasimod 1 mgEtrasimod 2 mgPlaceboTotal
Mean8.8 ± 1.438.9 ± 1.478.7 ± 1.728.8 ± 1.54
08

Study locations

134 sites
  • Arena 1119
    Birmingham, Alabama 35294, United States
  • Arena 1133
    Dothan, Alabama 36305, United States
  • Arena 1143
    Thousand Oaks, California 91360, United States
  • Arena 1107
    Hollywood, Florida 33021, United States
  • Arena 1138
    Miami, Florida 33134, United States
  • Arena 1123
    Naples, Florida 34102, United States
  • Arena 1141
    Orlando, Florida 32825, United States
  • Arena 1106
    Port Orange, Florida 32127, United States
  • Arena 1137
    Sweetwater, Florida 33172, United States
  • Arena 1131
    Chicago, Illinois 60611, United States
  • Arena 1139
    Hoffman Estates, Illinois 60169, United States
  • Arena 1127
    Urbana, Illinois 61801, United States
  • Arena 1142
    Traverse City, Michigan 49686, United States
  • Arena 1111
    Troy, Michigan 48098, United States
  • Arena 1109
    Great Neck, New York 11021, United States
  • Arena 1114
    Rochester, New York 14642, United States
  • Arena 1118
    Raleigh, North Carolina 27612, United States
  • Arena 1112
    Cincinnati, Ohio 45267, United States
  • Arena 1117
    Pittsburgh, Pennsylvania 15219, United States
  • Arena 1105
    Germantown, Tennessee 38138, United States
  • Arena 1102
    Hermitage, Tennessee 37076, United States
  • Arena 1136
    DeSoto, Texas 75115, United States
  • Arena 1121
    Houston, Texas 77030, United States
  • Arena 1116
    Temple, Texas 76508, United States
  • Arena 1103
    Ogden, Utah 84405, United States
  • Arena 1130
    Richmond, Virginia 23298, United States
  • Arena 1128
    Roanoke, Virginia 24014, United States
  • Arena 1115
    Seattle, Washington 98101, United States
  • Arena 1101
    Seattle, Washington 98195, United States
  • Arena 1108
    Wauwatosa, Wisconsin 53226, United States
  • Arena 1604
    Kingswood, 2747, Australia
  • Arena 1605
    Randwick, 2031, Australia
  • Arena 1607
    Subiaco, 6008, Australia
  • Arena 1490
    Wien, 1090, Austria
  • Arena 1472
    Edegem, 2650, Belgium
  • Arena 1464
    Kortrijk, 8500, Belgium
  • Arena 1473
    Löwen, 3000, Belgium
  • Arena 1421
    Ruse, 7002, Bulgaria
  • Arena 1409
    Sofia, 1407, Bulgaria
  • Arena 1410
    Sofia, 1407, Bulgaria
  • Arena 1417
    Sofia, 1407, Bulgaria
  • Arena 1407
    Sofia, 1797, Bulgaria
  • Arena 1425
    Varna, 9010, Bulgaria
  • Arena 1202
    Winnipeg, Manitoba R3A 1R9, Canada
  • Arena 1210
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • Arena 1206
    London, Ontario N6A 4G5, Canada
  • Arena 1208
    Sudbury, Ontario P3E 1H5, Canada
  • Arena 1209
    Sudbury, Ontario P3E 6C3, Canada
  • Arena 1204
    Toronto, Ontario M5G 1X5, Canada
  • Arena 1455
    Praha 4, 140 59, Czechia
  • Arena 1443
    Amiens Cedex 1, 80054, France
  • Arena 1418
    Clichy, 92110, France
  • Arena 1437
    Lille Cedex 1443, 59037, France
  • Arena 1476
    Paris, 75010, France
  • Arena 1480
    Pierre-Benite, 693110, France
  • Arena 1423
    Saint-Etienne Cedex 1, 42055, France
  • Arena 1457
    Vandoeuvre-les-Nancy, 54511, France
  • Arena 1479
    Hamburg, 20249, Germany
  • Arena 1422
    Hamburg, Germany
  • Arena 1470
    Hanover, 30625, Germany
  • Arena 1446
    Kiel, 24105, Germany
  • Arena 1489
    Leipzig, 04103, Germany
  • Arena 1497
    Oldenburg, 26123, Germany
  • Arena 1444
    Ulm, 89073, Germany
  • Arena 1478
    Bekescsaba, 5600, Hungary
  • Arena 1471
    Budapest, 1062, Hungary
  • Arena 1492
    Budapest, 1062, Hungary
  • Arena 1431
    Budapest, 1076, Hungary
  • Arena 1505
    Debrecen, 4025, Hungary
  • Arena 1474
    Debrecen, 4032, Hungary
  • Arena 1477
    Szombathely, 9700, Hungary
  • Arena 1705
    Beer Sheva, 84101, Israel
  • Arena 1702
    Haifa, 31096, Israel
  • Arena 1706
    Holon, 58100, Israel
  • Arena 1704
    Jerusalem, 91031, Israel
  • Arena 1703
    Petah-Tikva, 49100, Israel
  • Arena 1613
    Busan, 49241, Korea, Republic of
  • Arena 1614
    Daegu, 42415, Korea, Republic of
  • Arena 1610
    Incheon, 21565, Korea, Republic of
  • Arena 1612
    Seoul, 05505, Korea, Republic of
  • Arena 1611
    Seoul, 06519, Korea, Republic of
  • Arena 1608
    Suwon-si, 16247, Korea, Republic of
  • Arena 1615
    Wonju, 26426, Korea, Republic of
  • Arena 1462
    Riga, 1002, Latvia
  • Arena 1475
    Riga, 1006, Latvia
  • Arena 1484
    Vilnius, 8661, Lithuania
  • Arena 1601
    Christchurch, 8011, New Zealand
  • Arena 1439
    Bydgoszcz, 85-681, Poland
  • Arena 1486
    Elblag, 03-580, Poland
  • Arena 1495
    Kielce, 25-364, Poland
  • Arena 1451
    Krakow, 31-009, Poland
  • Arena 1438
    Lodz, 90-302, Poland
  • Arena 1458
    Posen, 61-485, Poland
  • Arena 1428
    Rzeszow, 35-068, Poland
  • Arena 1456
    Sopot, 81-756, Poland
  • Arena 1494
    Wroclaw, 54-144, Poland
  • Arena 1441
    Bucharest, 050098, Romania
  • Arena 1491
    Bucharest, 10719, Romania
  • Arena 1406
    Bucharest, Romania
  • Arena 1436
    Iasi, 700506, Romania

Showing the first 100 of 134 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kuhbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panes J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 Feb;158(3):550-561. doi: 10.1053/j.gastro.2019.10.035. Epub 2019 Nov 9. PubMed 31711921 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Feb 2018, 27 months.

Results were first posted in Apr 2021, 3 years 1 month after primary completion. A results delay was requested in Feb 2019.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 27 months is close to that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2015
First posted
May 18, 2015
StartActual
Oct 15, 2015
Primary completionActual
Feb 14, 2018
CompletionActual
Feb 14, 2018
Results delay requested
Feb 13, 2019
Results first posted
Apr 5, 2021
Last update
Apr 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02447302
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Oct 15, 2015
Primary completion
Feb 14, 2018
Completion
Feb 14, 2018
Results posted
Apr 5, 2021
Last update
Apr 5, 2021

Study contacts

Arena CT.gov Administrator
study director · Arena Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion